1Kappe R. Antifungal activity of the new azole UK-109,496 (voriconazole)[J].{H}MYCOSES,1999,(Suppl 2):83-86. 被引量：1
2Herbrecht R,Denning DW,Patterson TF. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[J].{H}New England Journal of Medicine,2002,(06):408-415. 被引量：1
3Walsh TJ,Lutsar I,Driscoll T. Voriconazole in the treatment of aspergillosis,scedosporiosis and other invasive fungal infections in children[J].{H}Pediatric Infectious Disease Journal,2002,(03):240-248. 被引量：1
4Purkins L,Wood N,Ghahramani P. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens[J].{H}Antimicrobial Agents and Chemotherapy,2002,(08):2546-2553. 被引量：1
5Ally R,Schurmann D,Kreisel W. A randomized,doubleblind,double-dummy,muhicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients[J].{H}Clinical Infectious Diseases,2001,(09):1447-1454. 被引量：1
6Walsh TJ,Karlsson MO,Driscoll T. Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration[J].{H}Antimicrobial Agents and Chemotherapy,2004,(06):2166-2172. 被引量：1
8Lazarus HM,Blumer J L,Yanovich S. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection:A dose escalation study[J].{H}Journal of Clinical Pharmacology,2002,(04):395-402. 被引量：1
9Ghannoum MA,Kuhn DM. Voriconazole-Better chances for patients with invasive mycoses[J].{H}European Journal of medical Reseasarch,2002,(05):242-256. 被引量：1
10Ostrosky-Zeichner L,Lashof A,Kullberg B J. Voriconazole salvage treatment of invasive candidiasis[J].{H}European Journal of Clinical Microbiology & Infectious Diseases,2003,(11):651-655. 被引量：1
